



# ARCS AUSTRALIA ANNUAL REPORT 2020-21



# CONTENTS

Performance Highlights 2020-21	3
Mission, Vision, Values and Goals	4
President's and CEO's Report	5
Education & Events	8
Pathways	12
Volunteers	14
Representation	15
Members	16
Partners	18
Information & Communication	19
Directors' Report	20
Financials	26

# PERFORMANCE HIGHLIGHTS 2020-21



**1,728**  
MEMBERS



**1**  
ANNUAL  
CONFERENCE



**101**  
EDUCATION  
EVENTS HELD

**2,198**  
ANNUAL CONFERENCE  
DAY VISITS



**2**  
SUMMITS



**976**  
INTEREST AREA  
MEETING  
REGISTRATIONS


**1,173**  
ANNUAL CONFERENCE  
INDIVIDUAL ATTENDEES



**428**  
ONLINE  
LEARNING  
STUDENTS



**8**  
NEW  
EVENTS



**91%**  
AVERAGE QUALITY RATING  
OF EDUCATION EVENTS

# MISSION, VISION, VALUES AND GOALS

ARCS Australia Ltd is a national, membership-based organisation focused on the development and growth of the healthcare sector. ARCS provides education, career pathways, professional development and advocacy to the healthcare sector.

Our membership is made up of individuals working in regulatory affairs, clinical research, health economics, medical information and other disciplines who work in the development and quality use of therapeutic goods. ARCS members are based in industry, academia, medical research institutes, government, hospitals and patient groups.

Through its members ARCS has a broad and effective reach throughout the healthcare sector, and provides a neutral forum to develop, agree and implement aligned policies and initiatives.

ARCS and its members are dedicated to improving the quality of life of healthcare consumers.

## VISION

A vibrant and engaged membership adding value to the healthcare sector

## MISSION

To provide education, career pathways, professional development and advocacy to the healthcare sector

## VALUES

ARCS is an individual membership-based organisation focused on a sector that provides medical technology and pharmaceuticals to the community. We believe it is important to hold ourselves, employees, volunteers and members to the highest professional and ethical standards through a statement of our core values.

We are committed to supporting our members and promoting our industry within these guiding values:

**INTEGRITY** – Adhere to the highest ethical standards. Through mutual respect, accountability and trust we foster a culture that adds value to our members and profession.

**EXCELLENCE** – Strive for quality through dedication to our work, continuous learning and improvement. We use our knowledge, expertise and evidence to guide our actions.

**LEADERSHIP** – Work to inspire our sector by being outwardly focused, engaging and collaborating with stakeholders. We draw on our members' knowledge and ideas to advance our sector.

**INFLUENCE** – Aim to innovate and lead change. We encourage members to actively participate through actions and ideas to improve the health of our community and the future of our sector.

## GOALS

1. To have a sustainable, skilled, connected and motivated professional workforce
2. To have a broad and effective reach in the traditional and emerging healthcare sector
3. To promote best practice implementation in digital strategy across the sector
4. To ensure sustainability of ARCS

## Acknowledgement of Country

ARCS acknowledges the traditional owners of the land on which we meet and work.

We pay our respects to Elders past, present and emerging.

# PRESIDENT'S AND CEO'S REPORT

The 2020-21 year will undoubtedly be seen as one of the most challenging in ARCS' recent history.

We are particularly proud of the ARCS team, a unique combination of staff and volunteers, who over the past 12 months have remained focused and resiliently supported members through the delivery of online programs, communicating the contribution of ARCS members to the sector and delivering a perfectly timed, face-to-face national conference in June.

This report provides an insight into the journey ARCS has been on over the past 12 months. We would also like to call out the great work many of the teams involved in the COVID clinical trials and regulatory submissions. Thank you to the ARCS team and our fantastic volunteers and members who worked so hard through these times.

Restrictions cut deep into the business operating environment threatening the livelihoods of many and requiring rapid change and adaptation. The primary focus for the 2020-21 year has been to ensure our organisation's viability and deliver high quality services to our members. ARCS was particularly concerned about keeping communication channels open and advocating across the sector to ensure that all aspects of our work can operate safely during the pandemic.

Despite the pandemic and disruption to everyone's lives, our members continued to invest in their professional development, were active contributors to Interest Areas and online learning – such a testament to our members' dedication.

## GOVERNANCE

At the November 2020 AGM, the ARCS Board welcomed Arthur Brandwood, Orin Chisholm and Adele Hosseini as non-executive directors for a 3-year term.

Three long serving directors, George Papadopoulos (President), Liz Joshi (Chair, Membership Committee) and Alex Lung (Chair, Finance and Risk Committee) retired. We acknowledged the significant contribution of both time and skill that each of our retiring directors have made. We are also reminded that directors, like many ARCS members, volunteer their time and we are grateful for their generosity and commitment to the organisation and its members.

At the first meeting of the newly constituted Board, Andrew Carter was elected President and Rob Kent was confirmed as Vice President. The Board also revised its committee structure and appointed new committee chairs (Governance – Rob Kent; Finance, Risk and Audit – Arthur Brandwood; and Strategic Initiatives – Marisa Petersen).

Thank you to all board members for their diligence, great work, insights, and support throughout the year. We acknowledge that the past 12 months has required more of our directors – particularly their time, and we appreciate their commitment to ensuring that ARCS met its financial responsibilities and organisational objectives.

## STRATEGY

In January 2021, the board and management commenced work on a comprehensive review of the organisation's strategic plan. The strategy work was underpinned by two workshops facilitated by Ian Adams (ARCS Life Member) and drew on a broad range of inputs from members.

Key to the new strategy is ensuring that ARCS engages with its members and the broader MTP sector in a contemporary way. Key to this will be employing the most appropriate technology, facilitating hybrid meetings where appropriate, and making information available to members easily and seamlessly.

## COVID RESPONSE

The COVID restrictions had a significant effect on ARCS and required flexibility and scenario planning often at short notice to keep pace with ever changing circumstances. All workshops and interest area meetings continued to be held as virtual events. Whilst we missed the face-to-face interactions with training participants it also opened the door to members across Australia.

After a short period of being able to return to the office, it was back to working from home. Due to the implementation of the new Office 365 applications, it provided a seamless transition from a technology point of view. Daily video calls were implemented to help keep in contact between the team members.

## FINANCIALS

Due to the significant disruption of the operating environment, considerable effort has been invested in the organisation's financial management. Diligent management of expenses was essential.

Due to a decline in revenue, ARCS was able to access various government support packages, including Job Keeper and a number of NSW State Government support packages.

ARCS was also successful in obtaining several state government grants designed to support NFP's, and grants focussed on delivering sector specific training workshops (MTP Connect REDI).

Through a combination of strict financial controls, a successful conference and various support packages, ARCS delivered a solid financial surplus without having to draw significantly on the reserves.

# PRESIDENT'S AND CEO'S REPORT *(cont.)*

## MEMBERS

At the end of the financial year 2021, ARCS recorded 1,728 members across all categories (1,563 Full Members). This compares to 1,785 (1,596) in FY 2020. Considering the hardships that COVID created it is a solid result which we will need to build on after some of the pandemic restrictions are lifted and after implementing some of the changes contained in the strategic plan.

Engagement of members with content and information increased with open rates for Member News and eJournal Cognition up on previous years.

In late 2020, ARCS conducted a targeted member survey to ensure that our goals continue to resonate with our members. We randomly selected 199 current members across all specialties and demographics and conducted the personalised survey with participants via Teams. The survey results validated that ARCS should maintain its current goals importantly though, the survey highlighted that the rapidly evolving health and medical research landscape underpins our members' thirst for high-quality educational services utilising various delivery platforms.

## VOLUNTEERS

We would like to call out the contribution of the ARCS volunteers and interest area convenors. Without their commitment, in time and expertise, content delivery in workshops, events, interest areas and the journal would be the poorer. The conference committee were not only involved in setting the agenda for the conference in June, but before that the agenda for the virtual summit. Volunteers are running workshops to improve skills development in the sector and share insights in interest area meetings.

This year during the conference the ARCS community spirit shone through and many industry colleagues stepped up to stand in for exhibitors and host sessions due to COVID related disruptions. We would like to express our gratitude to all those who volunteered at short notice and help make the conference the memorable event it turned out to be.

## EVENTS, ANNUAL CONFERENCE & VIRTUAL SUMMIT

ARCS held over 100 events with 8 new workshops launched, some of them with the support of our partners.

ARCS held three major events, two summits and the conference, each with its own unique logistical challenges and format but both successful in its own right.

### 2020 Virtual Summit

As the annual conference was not run, we needed to ensure we provided essential updates for the sector. We therefore developed an innovatively structured virtual summit in October 2020. This summit delivered topical presentations with each stream run for 1.5 hours per day over the week. This structure enabled people to attend the sessions but still manage the day-to-day needs in a pandemic stressed environment.

Over the week and in multiple streams over 1,200 registrations were recorded. Sponsors also took the opportunity to get in front of the virtual audience. This successful virtual event with a well-received program proved once again that ARCS was able to adapt quickly to changed circumstances.

### 2021 ARCS Annual Conference

In what turned out to be a small window of time, the annual conference was able to be run as face-to-face in Sydney at the International Convention Centre. The event was extremely successful with delegates, sponsors and exhibitors excited to meet with a real buzz in the air. Delegate numbers were on par with previous years despite the absence of Melbourne attendees due to the COVID restrictions. We were pleased to be able to run specific sessions for SMEs as well as a Careers Day for students and a large contingent from the public health sector. We were also pleased to again offer Consumer Scholarships. Bringing these groups to the conference brought a more complete ecosystem together, learning about the issues confronting each part of the sector.

Despite all of this, the event happened at a fortuitous moment during a global pandemic and brought almost all of the sector together in one venue.

Following the conference, we were able to make some of the recordings available as ARCS on Demand for those who couldn't attend or wanted to view additional sessions.



# PRESIDENT'S AND CEO'S REPORT *(cont.)*

## TECHNICAL CAPABILITIES

ARCS has embarked on an ambitious IT infrastructure plan to improve its online presence and services to members and the broader community. The first pieces of the IT puzzle were implemented this financial year with Office 365 including SharePoint and Teams to improve how we work together and capture our work to share with others. The next piece was a new events software that will enable the organisation to move the management of larger events like summits and the annual conference online and offer events, websites and apps from one system. Over time this will improve accessibility and user experience, and back office efficiencies. In the planning are a new member database and website including a new online community software and LMS which is all very exciting but requires a lot of planning, work and upskilling. We will have more to announce as this plan progresses.

Lastly, on behalf of the ARCS Board, once again we would like to extend our appreciation to the ARCS CEO and staff for their work and adaptability, to all the ARCS volunteers and others for their contributions, and especially to our members who have supported the association throughout yet another very turbulent COVID-affected year.

We wish everyone good health and happiness for the year ahead, hopefully one that will be less COVID affected. Rest assured that ARCS will remain dedicated to providing information, training and advocacy to members, partners and the health sector community.

We are looking forward to meeting you all in person or virtually at one of the ARCS events.



**Andrew Carter**  
President, ARCS Australia



**Shanny Dyer**  
CEO, ARCS Australia

A handwritten signature in blue ink, appearing to read 'Andrew Carter', written in a cursive style.

A handwritten signature in black ink, appearing to read 'Shanny Dyer', written in a cursive style.

# EDUCATION & EVENTS

This financial year continued to be dominated by COVID and remote working and learning. We built on the capabilities gained during the previous year during COVID restrictions to deliver 101 workshops and two summits as virtual events. This pivot to online delivery provided members and training participants with accessible, high-quality content and education so that skills could be improved, and attendees were able to connect to an online community of peers.

2020-21 has proven to be a productive year with the release of 8 new or significantly updated workshops which included:

1. Introduction to Regulation of In Vitro Diagnostic Medical Devices (IVDs)
2. Post-market Obligations of Medical Device and IVD Sponsors and Manufacturers
3. Applying Australian Safety Monitoring and Reporting Requirements\*
4. Project Management Essentials
5. Registration of Biologicals and Biotechnological Products
6. An Introduction to ISO 14155:2020
7. Effective Clinical Trial Study Start-up\*
8. Regulation of Pharmaceuticals in the USA

\*part of the ARCS partnership program



In addition to the virtual workshops, we delivered three major events

- **2020 ARCS Virtual Summit:** Learn Share Connect (12-16 October 2020)
- **Precision Medicine Summit** (4 parts in April-May 2021)
- **The 2021 ARCS Annual Conference** “From pandemic to recovery – building Australia’s competitive advantage post COVID” (7-9 June 2021, ICC Sydney) Conference

This year saw the introduction of the Patient Centricity Interest Area.

## Precision Medicine

A promotional graphic for the Precision Medicine Series. It features a stylized human figure composed of colorful dots, with a DNA double helix above it. The text reads: 'PRECISION MEDICINE SERIES', 'A virtual summit and Community of Practice', and lists four sessions: PMED 1 (28 April 2021), PMED 2 (5 May 2021), PMED 3 (12 May 2021), and PMED 4 (19 May 2021). It also states 'All sessions are at 12:00 - 13:30pm AEST' and 'Register now at: www.arcs.com.au'. The ARCS logo is in the bottom right corner.

The pace of change in the area of precision medicine continues to accelerate. ARCS held a four-part virtual summit to provide background to the precision health ecosystem, context around the key steps of the genomics value chain including sampling, sequencing, data analysis and interpretation, as well as information about the role of digital health in delivering improved patient outcomes. The series provided insights into the opportunities and risk associated with commercialising pharmaceutical precision and personalised medicines (gene therapies), as well as the ethical, legal and societal impacts to be considered during the clinical development, regulatory and reimbursement process.



## Virtual Summit



The **2020 ARCS Virtual Summit - Learn Share Connect** was held from 12-16 October 2020. This virtual event was comprised of a series of streams over a week in October 2020. A set of sessions on a topic area became a stream. Delegates could select a stream and, over the week, attend 5 sessions at the same time daily with a different topic each day. This way attendees did not need to commit for an entire day but still felt like being involved in a virtual conference-style event. The 2020 ARCS Virtual Summit brought together industry, regulator, academia and researchers to educate, network and unite in a time of change. It provided essential and timely information in each of the key educational areas – particularly as we traverse the issues associated with the COVID-19 pandemic as well other local and international issues. One of the benefits with a virtual event is the ability to invite a strong and compelling line up of international speakers providing a global perspective.

- A. Clinical Research Breakfast Bites Series
- B. Real World Evidence & its impact on clinical, regulatory and market access
- C. Innovations in clinical trials: Beyond COVID-19
- D. Essential updates for regulatory medicine professionals (including the impact of COVID-19)
- E. Essential updates (including EU MDR) for regulatory medical device professionals
- F. Leadership in times of change (Dine and Develop Series)



### Attendee statistics:

- 1,264 stream registrations
- 692 unique logins
- 78-minute average visit duration
- There were over 2,700 views on the exhibitor booths

### Key metrics:

Rated as 'Excellent / Very Good'

- Ease of use of Summit platform: 84.9%
- Polling features: 70%
- The Interactive (engagement) Points Challenge: 77.67%
- Virtual exhibition: 66.67%



## Annual Conference



**The annual conference was held from 7-9 June 2021 at the ICC Sydney (NSW) with the theme of *From pandemic to recovery – building Australia's competitive advantage post COVID.***

2020 will forever be the year of COVID. The pandemic impacted the world socially, environmentally and economically – the ramifications of this will be felt for decades to come. It changed the way we work, live and set us on a course of the 'new normal'. But what is the new normal? Of the changes, what do we keep and what do we throw out?

As devastating the pandemic was, the disruption it caused had many positive outcomes.

This pandemic has exemplified the need for translational medical research, clinical trials and key infrastructure that can be mobilised in a time of crisis. On top of this we have an ageing population and rising prevalence of chronic diseases, juxtaposed with a need for critical infrastructure investments, technological advancement, evolving care models, staff shortages, and the expansion of healthcare systems in developing markets. These elements create opportunity and uncertainty.

Governments support innovation by investing in enablers such as education & skills development, science and research, and infrastructure; incentivising business investment and removing regulatory obstacles. A more innovative Australia will improve the quality of life for Australians reaching from cities and regions to rural and remote communities.

Are we using funding as effectively as we can and are we developing the right policies to drive innovation?

At its best, the integration of innovative technologies and systems enable the adoption of better healthcare in Australia – improving quality of life. It may also provide a global competitive advantage in growth areas such as clinical trial design, telemedicine, precision medicine and genomics. Australia already has an international reputation for exemplar medical research. Through strategic investment and coordinated management of national and state policies, Australia can build on its reputation for medical research and become a leader in these areas.

Large multinational companies and Australian SMEs developing new and exciting therapies need to have a stable and predictable but innovative environment to trial and invest in new therapies. The Australian Government can provide such an environment which will be critical for our ongoing healthcare innovation. As part of this environment, patient centricity and democratisation of healthcare is fundamental to our future and the global impact we can have on people's lives.

2021 ARCS featured 88 individual sessions in 7 parallel streams over three days covering regulatory, clinical research, health economics & reimbursement, leadership and other health topics. The conference also included a dedicated SME stream, Careers Day including student scholarships to attend, patient scholarships to attend, and social functions including the Awards Dinner and exhibition.



## MTP Sector Awards

MTP Sector Award nominations were open for:

- Innovation Award (2 categories)
  - a. Individual
  - b. Organisation

This award is to acknowledge individuals or groups who showed creativity, resolve and resilience to solve what seemed like intractable issues in the face of the COVID pandemic.

- Leadership Award (2 categories)
  - a. Individual
  - b. Organisation

This award acknowledges individuals or groups who astutely identified adverse issues faced by their organisation as the lockdowns forced WFH and who implemented sustainable changes with positive outcomes for both employees and the organisation.

Congratulations to all 2021 MTP Sector Awards in the Innovation and Leadership categories:

- Innovation Award - Individual:  
Kylie Sproston, CEO, Bellberry Ltd
- Innovation Award - Organisation:  
NSW Health Pathology
- Leadership Award - Individual:  
Nick Ward & Johanna Hann,  
Co-Directors, PharmaToMarket

Exhibition Awards:

- Best Booth Award: Akesa
- Best New Exhibitor Award(s): Veeva & OpIn (Opyl)



# PATHWAYS

## REGULATORY

HEAD/DIRECTOR  
REGULATORY AFFAIRS

Regulatory Affairs Manager

Regulatory Affairs Team Leader

Senior Regulatory Affairs Associate

Regulatory Affairs Associate

Regulatory Affairs Assistant

## CLINICAL RESEARCH

HEAD/DIRECTOR  
CLINICAL RESEARCH

Clinical Research Manager

Clinical Research Team Leader

Study Start Up Specialist

Clinical Project Manager

Clinical Research Associate /  
Senior Clinical Research Associate

Clinical Trials Assistant

## PHARMACOVIGILANCE

COUNTRY  
SAFETY LEAD

Pharmacovigilance Manager

Senior Pharmacovigilance Associate

Pharmacovigilance Associate

### ARCS PROFESSIONAL DEVELOPMENT COURSES FOR REGULATORY PROFESSIONALS

Medicines      Devices

Overview of the MTP Sector	Medicines	Devices
Introduction to Australian Regulatory Affairs – Prescription Medicines	Medicines	
Introduction to Australian Regulatory Affairs – Non-prescription Medicines	Medicines	
e-Submissions for the Regulatory Professional	Medicines	
Introduction to Regulatory Affairs in Australia for Medical Devices		Devices
Introduction to Regulation of In Vitro Diagnostic Medical Devices (IVDs)		Devices
Project Management Essentials	Medicines	Devices

### PROFESSIONAL DEVELOPMENT FOR CLINICAL PROFESSIONALS

Investigational Site      Sponsor / CRO

Overview of the Medical Technology and Pharmaceutical Sector	Investigational Site	Sponsor / CRO
Overview of Drug Development	Investigational Site	Sponsor / CRO
Clinical Trial Assistant – The Essentials	Investigational Site	
Applied GCP Training for Investigational Sites and Sponsor Representatives E6 (R2) <sup>1</sup>	Investigational Site	Sponsor / CRO
Conducting Clinical Research – Essential GCP Training for New Coordinators and Researchers E6(R2) <sup>1</sup>	Investigational Site	
Essential and Practical GCP Training for New Monitors and CRAs	Investigational Site	Sponsor / CRO
An Introduction to ISO 14155:2020	Investigational Site	Sponsor / CRO
Introduction to Early Phase Clinical Research	Investigational Site	Sponsor / CRO
Essential Documents and Good Documentation Practice	Investigational Site	Sponsor / CRO
Project Management Essentials	Investigational Site	Sponsor / CRO

<sup>1</sup> The ICH E6 GCP Investigator Site Training meets the Minimum Criteria for ICH GCP Investigator Site Personnel Training identified by TransCelerator. Bio-Pharma is necessary to enable mutual recognition of GCP training among trial sponsors.

### PROFESSIONAL DEVELOPMENT FOR PHARMACOVIGILANCE PROFESSIONALS

Overview of the Medical Technology and Pharmaceutical Sector	
Overview of Drug Development	
An Introduction to Pharmacovigilance: A Theoretical Approach	

# VOLUNTEERS

Thank you to all volunteers, convenors and others who helped out in any way by donating time or expertise to ARCS and its members in 2020-21. Special mention to all who volunteered at the 2021 ARCS Annual Conference.

## Interest Area convenors:

The regular ARCS interest areas play a vital role within the organisation and all have an interest area convenor/s. All meetings are via webinar and typically include a short ARCS office update on upcoming events and activities followed by an educational discussion topic. These discussion topics are great ways of staying across issues which affect us. These meetings are free for all ARCS members and form part of your membership benefits. Meetings are typically run from 12:30 – 1:30pm, on the first & third Tuesday and the second & fourth Thursday of each month except in late December or January.

### ASIA PACIFIC

- Jon Carrano, Managing Director, Pharmsite
- Terri Davies, Senior Project Manager, Icon Clinical Research

### CONSUMER PARTNERSHIP

- Janelle Bowden, Managing Director and Consultant, AccessCR

### CLINICAL RESEARCH

- Annie Shelton, Senior Clinical Research Associate, IQVIA
- Laura Castro, Senior Clinical Research Associate (Medical Devices), Zimmer Biomet

### HREC / GOVERNANCE

- Sonia Hancock, Manager, Research Integrity and Compliance, Metro South Health

### LEADERSHIP

- Samantha Flynn, Director of Project Management, ICON
- Sebastien Ducarme, Global Patient Partnership Director, Roche

### MEDICAL WRITING

- Belinda Butcher, Director, WriteSource Medical

### PHARMACOVIGILANCE

- Maria Creaton, PV Compliance Manager, AbbVie
- Kavitha Sivasankaran, Associate Director, Global Pharmacovigilance Lead ANZ, MSD

### REGULATORY AFFAIRS

- Michelle Hyatt, Regulatory Affairs Manager, Viatrix (Alphapharm)
- Karen Lam, Senior Regulatory Affairs Associate, AbbVie

## State Networking Groups

State Networking Groups meet to network and discuss latest news and developments. These groups significantly contribute to the association in by connecting members across industry sectors. Each group is hosted by a volunteer convenor and supported by an ARCS staff member.

- QUEENSLAND: Daina Vanags, Director of Regulatory Affairs, General Manager ERA Consulting (Australia)
- VICTORIA: Jacqui Cumming, Head of Clinical, iGENÜ CRO
- SOUTH AUSTRALIA: Priyanka Chamoli, Director Quality Assurance, Avance Clinical
- WESTERN AUSTRALIA: Kathryn Jajko, Research Lead - Radiation Oncology, GenesisCare

## Annual Conference Advisory Panel

The advisory panel for the annual conference in 2021 included:

- Amne Alrifai, Director, Avicenna Consulting
- Deama Amr, Senior Clinical Research Manager, Medtronic
- Jessica Bean, Chairperson, Patient Voice Initiative
- Gary Burgess, Director of Corporate Regulatory Affairs, Cochlear
- Terri Davies, Senior Project Manager, Icon Clinical Research
- Maria Dionyssopoulos, Head of Regulatory, Quality & Compliance, Commercial Eyes
- Stephen Firmer, Director, Asia Pacific Consultants
- David Grainger, Adviser and Board Chair, Biointelect, Sydney Australia
- Sonia Hancock, Manager, Research Integrity and Compliance, Metro South Health
- Annette Jones, Associate Director, Clinical Trials Support, Sydney University
- Nastassia Lukass, Patient Safety Manager, AstraZeneca
- Tam Nguyen, Deputy Director of Research, St Vincent's Hospital, Melbourne
- Mary Nteris, Director, Enimera RegsPlus
- Carolyn Tucek-Szabo, Executive, Head of Regulatory Affairs, Australasia, Glaxo Smith Kline Pharmaceuticals
- David Wilks, Head of Clinical Operations, RCO Pacific (Australia, New Zealand, Singapore & India), Bristol Myers Squibb

# REPRESENTATION

## Representation on external panels and committees

The ARCS office staff and CEO worked on a number of initiatives and activities related to the therapeutics environment and healthcare. These involved:

- Leadership in the R&D Taskforce – an initiative of Medicines Australia and MTAA
- Education Affiliate to MTP Connect
- Scientific Advisory Committee for the Pharmaceutical & Medical Device Development Masters, Graduate Diploma and Graduate Certificate Program at the University of Sydney
- Chair of the Board of the ARC Training Centre for Innovative Bioengineering
- Panel Member, ARC ITTC 2020
- Advisory board member, Master of Pharmaceutical Industry Practice, The University of Queensland
- Committee member, Pharmaceutical Sciences Industry Advisory Committee, RMIT
- Committee member, 'HE-030: Biological and Clinical Evaluation of Medical Devices'

ARCS made a submission to the *Inquiry into approval process for new drugs and novel medical technologies in Australia* by the House of Representatives, Standing Committee on Health, Aged Care and Sport (12 October 2020).

As in the previous year, most of the sector conference and events were affected, postponed or cancelled due to COVID-19. ARCS Australia represented members and the sector at the following events:


- SCRS, 2020 ANZ Virtual Summit Series (09, 16, 23, 30 July 2020) – attended
- MedTech20 Virtual Conference, Virtual (28 – 30 October 2020) - attended
- Australian Healthcare Week, ICC Sydney (17 – 18 March 2021) – attended
- Biointelect/Pfizer ROUNDTABLE: Response and resilience of the Australian life science sector (25 March 2021)
- AusMedtech (AusBiotech), virtual (17 – 21 May 2021) – chaired session
- International Clinical Trials Day (ACTA), Melbourne (20 May 2021) - attended
- International Clinical Trials Day (St Vincent's), Melbourne (20 May 2021) – panelist




# MEMBERS

Members are at the heart of everything ARCS Australia does. Our vision is to create a vibrant and engaged membership adding value to the healthcare sector.


## Membership types




## Distribution of members




## Member seniority



## Member overview by year



## Member education interests



## Membership Survey

In late 2020, ARCS conducted a targeted member survey to ensure that our goals continue to resonate with our members. We randomly selected 199 current members across all specialties and demographics and conducted the personalised survey with participants via Teams. The participation rate was 19%, higher than market research benchmarks.

The survey results validated that ARCS should maintain its current goals:

- having a sustainable, skilled, connected and motivated professional workforce;
- having a broad and effective reach in the traditional and emerging healthcare sector;
- promoting best practice in the implementation in the digital strategy across the sector;
- ensuring the sustainability of ARCS.


Importantly though, the survey highlighted that the rapidly evolving health and medical research landscape underpins our members' thirst for high-quality educational services utilising various delivery platforms.

Survey results highlighted that the key pillars of ARCS current and future success include:

- The Annual Conference, augmented by digital delivery of educational services;
- ARCS advocacy role remains highly valued by 92% of survey participants;
- Expanding our membership from the current NSW/VIC centric model by the ongoing delivering of digital education;
- Popularity of on-demand learning as many members are time poor;
- Ensuring delivery of high-quality content across all levels of seniority;
- The value ascribed to ARCS' proposed provision of accredited courses and micro-credentialing, i.e. this increased from 43% in the 2016 Survey to 73% in the 2020 Survey;
- The implementation of career pathways and facilitation of peer collaboration.

ARCS is motivated to harness the insights provided by the survey participants and other metrics. We will develop a roadmap of prioritised actions, clearly articulate our value proposition and use technology to optimise member engagement.

## Member survey results



# PARTNERS

ARCS has actively built partnerships with key stakeholders in the healthcare sector. We believe that we can make a difference to the sector and add value to our members for example through education opportunities.

## Partners



The partnership program aims to:

INFLUENCE

UNIFY

ENGAGE

UP-SKILL

INFORM

RECOGNISE

EDUCATE

## Educational Partners



## Media Partner


**AUDIENCED**

# INFORMATION & COMMUNICATION

ARCS issued a range of newsletters and information services each week. The weekly Member News (formerly CEO, News & Jobs Bulletin) and the quarterly eJournal Cognitio are only available to members, whereas the fortnightly Events Bulletin is sent to an open subscription list. The Events Bulletin has a subscriber base of over 6,000. Four editions of Cognitio were published in 2020-21.

ARCS has increased its social media presence on LinkedIn, Twitter, Instagram and YouTube.

## ARCS Website Audience overview: | July 2020 – 30 June 2021 |



Overall, the stats show global positive trends for ARCS users. More than 50k users visited the ARCS website in the last year. 82.6% are new users and 17.4% returned more than once on the ARCS website.

This is an increase of 2k visitors (with 677k page views) compared to last years report. Peak time was in June around the Annual Conference.

In the last FY, users generated more than 88K session interactions with ARCS. With users visiting at least 7 pages per session and spent just under

3 minutes per session on the website. Most viewed section on the ARCS website was the 2021 Conference Section.

### TOTAL POSTS

**789**

The total number of posts that ARCS have published across all social media channels.

### TOTAL FOLLOWERS

**5,708**

The number of people who are following ARCS on social media.

### TOTAL ENEGAGEMENT

**6,542**

Engagements include likes, comments and shares on posts.

### TOTAL IMPRESSION

**296k**

An impression is when a post is visible in a social feed. This is how many people saw the ARCS brand across all social channels.



**LinkedIn**  
Total followers  
**4.2k**



**Twitter**  
Total followers  
**1.1k**



**Instagram**  
Total followers  
**408**

# DIRECTORS' REPORT

The Directors of ARCS Australia Limited (ARCS) present this report and the Financial Statements of the Company for the year ended 30 June 2021.

## I. DIRECTORS 2020-21

The details of the directors who held office during or since the end of the financial year are provided in Table I. Six scheduled board meetings in total were held between July 2020 to June 2021 with one additional extraordinary meeting in September 2020.

**Table I: Board Meetings 1 July 2020 – 30 June 2021**

Name	Association	Commencement	Cessation	A (B)	Key Activities
Elizabeth Joshi	Bayer ANZ Sandoz	26 Nov 2015	18 Nov 20	2 (2)	Chair, Membership & Education Committee (as of 27 Nov 2019) Corporate Governance Committee (as of 27 Nov 2019)
Robert Kent	The Kinghorn Cancer Centre	31 July 17		7 (7)	Vice President (as of 27 Nov 2019) Chair, Membership & Education Committee (until 27 Nov 2019) Chair, Governance Committee (as of 27 Nov 2019)
Alex Leung	CareFusion Hologic	26 Nov 2015	18 Nov 20	2 (2)	Chair, Audit & Risk Management Committee Company Secretary
George Papadopoulos	Emerald Corporate Group	26 Nov 2014	18 Nov 20	2 (2)	President (until 18 Nov 20) Membership & Education Committee (until 27 Nov 2019) Corporate Governance Committee (28 Nov 19-18 Nov 20)
Andrew Carter	Commercial Eyes Pty Ltd	27 Nov 2019		7(7)	President ( from 18 Nov20) Member, Finance, Risk & Audit
Marisa Petersen	Retired	27 Nov 2019		7(7)	Chair, Strategic Initiatives Member, Finance, Risk & Audit
Arthur Brandwood	Retired	19 Nov 2020		7 (7)	Chair, Finance, Risk & Audit
Orin Chisholm	Consultant	19 Nov 2020		7 (7)	Member, Finance, Risk & Audit Member, Strategic Initiatives
Adele Hosseini	Scientific Director, BOD Australia	18 Nov 2020		7 (7)	Member, Governance Member, Strategic Initiatives

A: meetings attended from B meetings held

# DIRECTOR BIOGRAPHIES



## President: ANDREW CARTER

(from 19 November 2020)

Andrew is the Founder and Managing Director of Commercial Eyes with nearly 30 years' experience in the medicines and medical device industry. He is a highly qualified and skilled business leader and company director, with nearly twenty years of governance experience in both the private and public sector. Andrew is a current member of the Medicines Australia Advisory Council and the University of Melbourne, Master of Biotechnology Advisory Board, past Chair of BioMelbourne Network Inc (a Victorian life science industry association with over 220 member companies) and past member of Medicines Australia's Strategic and Access Committees, QUM and Continuing Education Working Groups, and the National Prescribing Service Medicines Industry Liaison Group. He is active in social justice and delivery of disadvantaged support services. Past directorships include: Chair of Melbourne City Mission Ltd (a Victorian organisation that employed 700+ staff and delivered vital services in Disability, Homelessness, Justice, Residential Aged Care, Palliative Care and Education); Chair of MCM Housing Association Ltd; Chair of the Melbourne CBD Youth Refuge Advisory Committee; Member of the Committee for Melbourne Not for Profit Taskforce; Councillor of Whitley College, University of Melbourne. Recipient of the Pat Clear Award for services to the Australian Medicine Industry (2014).



## President: GEORGE PAPADOPOULOS

(to 18 November 2020)

George has more than 25 years' experience in the pharmaceutical industry including clinical research, health economics, reimbursement, pricing and business development. He has worked in both the local operating company and global levels in increasing levels of responsibility. He has worked for leading pharmaceutical companies in Australia, Belgium and the United States including Pharmacia, Johnson & Johnson, Schering-Plough and Merck. George is the Managing Director of Emerald Corporate Group, a strategic consultancy providing services to assist healthcare companies with the market access for their pharmaceutical, medical device or diagnostic technologies.

George received his BSc (Hons) from the University of Sydney and Grad Dip Epi (Pharmacoepi) from University of Newcastle. He is the Treasurer of ISPOR Australian Chapter and an active member of HTAi (Health Technology Association International), iHEA (International Health Economics Association) and a member of the AICD (Australian Institute of Company Directors).

George is a member of the Audit and Risk Management Committee and Membership and Education Committee of ARCS.



## Company Secretary: ALEX LEUNG

Alex has more than 20 years' of experience in leadership roles in quality and regulatory affairs in Asia Pacific, Alex led a network of

quality and regulatory professionals in Sydney, Tokyo, Beijing, Shanghai and Shenzhen, set long-term regulatory strategies to complement business growth in the region. In addition to the matured markets of Australia/New Zealand and Japan, Alex is also responsible for China and other emerging markets in Asia, including India, Taiwan, South Korea, Hong Kong, ASEAN.

Alex holds bachelor's degree in engineering from the UK, master's degree in engineering from the USA and MBA from Australia.

Alex is the Company Secretary of ARCS and is Chair of the Audit and Risk Management Committee. Alex also participates in a Standards sub-committee on behalf of ARCS.



## Vice President: ELIZABETH JOSHI

Liz has over 18 years of regulatory affairs experience working in Australia and NZ in pharmaceuticals and the consumer care

sector. Her key roles have been in new product registrations, orphan designation, mergers, organisational efficiency, high-impact cross-functional interactions on scheduling and major regulatory reform. Liz has led multiple negotiations for best product labels across the world, and has provided direction and enabled effective regulatory strategies to support key product launches and issue management.

During her career Liz has shown strong leadership, communication and inter-personal skills with a passion for people development through knowledge sharing and continuous improvement.

Liz is a prominent member of the industry group who supports and drives professional development in partnership with the health authority. She has been instrumental in a number of policy reforms on regulatory burden and improved certainty of supply. She has also overseen the development of eCTD and RMP new interest area groups to meet ARCS' membership needs.

Liz holds a Bachelor's and Master's degree in pharmacy, specialising in pharmaceuticals. She has been an active ARCS contributor since 2006 – she was the co-convenor of an ARCS education sub-committee in 2008 and was elected to the Board of Directors in 2015.

# DIRECTOR BIOGRAPHIES



## Vice President: ROBERT KENT

Robert has over 25 years of clinical and research experience. Since 2005, Robert has worked in roles such as Research Coordinator and Senior Clinical Research Associate for both academic and commercial institutions, in Australia and overseas. In 2011 Robert was appointed as the Research Manager at The Kinghorn Cancer Centre in Darlinghurst. Leading a dynamic clinical trials department, Robert is responsible for building site capabilities and the rapid expansion of the centres Phase I unit as part of the NSW NECTA collaboration. He currently manages a large portfolio Phase I – III Industry trials, as well as developing and managing multi-centred national & international Investigator led research.

Robert has been an active volunteer for ARCS since 2005 and a Human Research Ethics Committee member since 2015. Robert brings a focus on site and regulatory issues to the board to add to the representation of ARCS diverse membership.



## MARISA PETERSEN

With 30 years in clinical trial management and business leadership in the Asia Pacific region Marisa has worked with and led several small to medium sized companies and organisations, focusing on strategic leadership with development of achievable medium and long term goals to guide the businesses. This has included growing businesses, ensuring financial sustainability, nurturing stakeholder relationships across healthcare, government and related organisations (Austrade, APPA, ACTA) and actively engaging on Committees such as the Pharmaceuticals Industry Council to advocate for more streamlined processes aimed at making Australia competitive in the global business of therapeutics development. Prior to her leadership roles, Marisa worked in the pharmaceutical industry fulfilling roles in Regulatory Affairs, Clinical Research and Project Management in the Australian and Asia-Pacific operations of global CROs, and also developed a network of offices across the Asia-Pacific region.



## ORIN CHISHOLM

Orin is an experienced regulatory scientist with expertise in registering innovative medicines in oncology and women's health across both large and small biopharmaceutical organisations. She has been in regulatory affairs since 2000. She is a well-recognised educator in pharmaceutical medicine, medical affairs, regulatory affairs, personalised medicine, oncology and gene technology.

She has recently completed three years on the Gene Technology Technical Advisory Committee of the Office of the Gene Technology Regulator. Orin is a recipient of the TOPRA (The Organisation for Regulatory Affairs Professionals, UK) Award for Excellence in Regulatory Affairs Education and is a Senior Fellow of the Higher Education Academy (UK). Orin has an adjunct appointment at Arizona State University, USA. Orin has a Bachelor of Science degree with Honours in biochemistry and a PhD in the molecular biology of cancer from the University of Sydney, as well as a Graduate Certificate in University Learning and Teaching from UNSW Sydney.

Orin is currently responsible for development and delivery of postgraduate education in pharmaceutical medicine. She is also a regulatory affairs consultant and provides advice to clients on regulatory issues.



## ADELE HOSSEINI

Adele is a PhD pharmacist with over 17 years foundation in leadership, global clinical research, regulatory affairs and university lecturing, providing exposure across pharmaceuticals, clinical research organisation, medical devices and academia. Her extensive corporate exposure has equipped her with expertise in governance, strategic direction, policy development, financial sustainability and stakeholder engagement. She is a highly experienced executive scientific and clinical affairs professional with significant senior leadership managing the strategic direction and quality implementation of multifaceted, global clinical trials and programs.

Adele is currently the Chief Scientific Officer at Bod Australia, leading the R&D program and drug development strategy to meet the company's mid and long-term goals. This includes the strategic direction for current and future technology and Chair the Bod Australia Medical Advisory Board.

# DIRECTOR BIOGRAPHIES



## ARTHUR BRANDWOOD

Arthur Brandwood has served the therapeutics industry for over 35 years: in biomaterials and product R&D, as Director of Devices Registration and Assessment at TGA and through a business career

spanning more than two decades including as Director and Principal Consultant of Brandwood CKC and a number of board and advisory roles.

At TGA Arthur was closely involved in the initial development of the current regulations for medical devices. He is actively engaged in Australian regulatory policy, including as past Chair of the National Advisory Board for AusMedtech with a leading role in dialogue with government. Internationally, Arthur provides training and advice to regulatory authorities and is Senior Adviser to the Asian Harmonization Working Party. His contributions have been recognised through an Outstanding Professional Contribution Award from China FDA and award of Fellow of the US Regulatory Affairs Professional Association.

Arthur is Visiting Professor in Engineering at University of Sydney teaching regulatory affairs, and Honorary Fellow at University of Melbourne. He serves on the Industry Advisory Boards in biomedical engineering for both Universities.

## 2. PRESIDENT

George Papadopoulos held the role of President until 18 November 2020. When George stood down, Andrew Carter was elected President on 19 November 2020. Robert Kent remained in the position of Vice President.

## 3. COMPANY SECRETARY

Alex Leung has held the role of company secretary since 13 December 2016. When Alex stood down, the role was taken on by the CEO, Shanny Dyer.

## 4. BOARD COMMITTEES

In January 2020, the board approved a revision of the committee focus. The changes were:

The Corporate Governance Committee (Chair Robert Kent) now the Governance Committee.

The Audit, Risk Management Committee (Chair Arthur Brandwood) now the Finance, Risk and Audit Committee.

The Membership and Education Committee (Chair Marisa Petersen) now the Strategic Initiatives Committee. Under clause 16.1 (a) of the Constitution, Ian Adams (Life Member) was appointed to the Strategic Initiatives Committee on 12 March 2021 for a one-year term to assist with the development of the new strategy.

## 5. SHORT- AND LONG- TERM OBJECTIVES AND STRATEGY

In 2017, the board approved a new vision and mission. These core statements were supported by the development of the 2018-23 strategy. In light of the pandemic, the board decided to review the strategy to ensure appropriate alignment and relevance. This work was undertaken in Q4 of the financial year and the outcomes will roll into the FY22 period for finalisation.

The focus and strategy as determined in 2017 remains with the 4 key goals:

1. To have a sustainable, skilled, connected and motivated professional workforce
2. To have a broad and effective reach in the traditional and emerging healthcare sector
3. To promote best practice implementation in digital strategy across the sector
4. To ensure sustainability of ARCS

Integral to our strategy are our values of integrity, excellence, leadership and influence. With these values in mind, we have undertaken the following principal activities.

## 6. PRINCIPAL ACTIVITIES

ARCS Australia Ltd is a national, membership-based organisation focused on the development and growth of the healthcare sector. ARCS provides education, career pathways, professional development and advocacy to the healthcare sector.

Our membership is made up of individuals working in regulatory affairs, clinical research, health economics, medical information and other disciplines who work in the development and quality use of therapeutic goods. ARCS members are based in industry, academia, medical research institutes, government, hospitals and patient groups.

Through its members ARCS has a broad and effective reach throughout the healthcare sector, and provides a neutral forum to develop, agree and implement aligned policies and initiatives.

ARCS and its members are dedicated to improving the quality of life of healthcare consumers.

The company's principal activities during the year were:

- Running a Virtual Summit in October 2020. This event was in place of an annual event in FY2020 which was not able to be held due to the pandemic.
- Holding the 2021 ARCS annual conference in June. This event covered clinical research, regulatory affairs, medtech, health economics and Quality/GMP with the addition of 20 patients/consumers attending through scholarships. A Careers Day was held for students and a specific stream for SME's. Both sessions were run to increase knowledge of the sector. The theme of the conference was 'From Pandemic to Recovery, Building Australia's capability post COVID'.
- The transition to and delivery of virtual workshops, interest area meetings, peer-to-peer events and webinars. No face to face networking events were held due to the pandemic.
- Representation of members interest at government meetings and forums.
- Continuation of the Senior Clinical Research Managers (SCRuM) meetings.

These activities have assisted the company in achieving its objectives by:

- Providing high-quality, relevant, and current education programs that are targeted to specific member groups
- Providing opportunities for members to exchange information and collaborate with peers from the sector
- Providing information relevant to members
- Representing member interests in significant areas
- Providing an interactive website that hosts a multitude of member only resources, training material, collaborative forum and professional development tracking process.

## 7. PARTNERSHIPS, RELATIONSHIPS AND COLLABORATIONS

In 2016, the Board approved the development of partnerships while continuing strong relationships and collaborations with key stakeholders, including both federal and state governments, the Therapeutic Goods Administration (TGA), OGTR, MTP Connect and other sector peak bodies.

The purpose of the partnerships, relationships and collaborations was to connect and strengthen the sector where there is often fragmentation and disconnect. ARCS aims to ensure that communications across the sector are transparent and equitable enabling us to assist and maintain value and relevance to the Australian marketplace to ensure:

- Collaboration between industry, government and academia hospitals and MRIs to improve the clinical research framework.
- Growing the breadth and depth of educational offerings through the expertise of the partners.
- Expanded relationship with key government regulators such as TGA and OGTR.
- Expanding relationships with key stakeholders such as state and federal health departments, MTP Connect and peak bodies
- Ability to influence the direction of the sector both nationally and internationally.

By the end of June 2021, the following partnerships were maintained with the addition of one new partner, HealthMatch:

- AWJ Insurance
- Biointellect
- Brandwood CKC (now PharmaLex)
- Cochlear
- Copyright Agency
- Cryosite
- Global Data
- GroworX
- HealthMatch (new to FY21)
- IQVIA
- Novotech
- St Vincent's Hospital

Collaborative relationships in place with:

- AHRDMA
- APPA
- DIA
- MTP Connect
- ISPE
- RACI
- SCRS
- Audiened (Media Partner)

ARCS will continue to build bridges with all relevant organisations and health consumer groups.

## 8. PERFORMANCE MEASURES

The company measures performance as follows:

Metric	FY18	FY19	FY20*	FY21*	trend
Number of members	1,792	1,869	1,785	1,728	↘
Educational events held (workshops, webinars etc)	133	125	110	101	↘
Updated/new events	6	6	1	8	↗
Conference	1	1	1	1	↔
Summits				2	
Attendees at conference (day visits)	990 (1,911)	1,158 (2,216)	1,170 (2,255)	1,173 (2,198)	↔
Online learning	639	611	549	428	↘
Attendance at interest area meetings	1,862	1,602	1,103	976	↘
Quality rating of education events	93%	92%	94.6%	91%	↘

\*outcomes for these financial years have been significantly affected by the COVID-19 pandemic

## 9. MEMBERS' GUARANTEE

In accordance with the Company's constitution, each member is liable to contribute an amount not exceeding \$10.00 in the event that the Company is wound up. On the basis of membership numbers at 30 June 2021, the total amount members would contribute is \$17,280.

## 10. AUDITORS' INDEPENDENCE DECLARATION

The auditor's independence declaration for the year ended 30 June 2021 has been received and is attached. This Directors' Report is made and signed in accordance with a resolution of the Board of Directors made pursuant to the Australian Charities and Not for Profit Commission (ACNC).



Director

21 October 2021



**ARCS AUSTRALIA LIMITED**  
**ABN 25 050 334 444**

**FINANCIAL REPORT - 30 JUNE 2021**

**CONTENTS**

Statement of Financial Position	1
Statement of Profit or Loss and Other Comprehensive Income	2
Statement of Changes in Funds	3
Statement of Cash Flows	4
Notes to the Financial Statements	5
Directors' Declaration	16
Independent Auditor's Report	17

**ARCS AUSTRALIA LIMITED****ABN 25 050 334 444****STATEMENT OF FINANCIAL POSITION****AS AT 30 JUNE 2021**

	Note	2021 \$	2020 \$
<b>ASSETS</b>			
<b>Current assets</b>			
Cash and cash equivalents	6	534,000	302,615
Trade and other receivables	7	451,279	263,528
Financial assets	8	669,031	574,252
<i>Total current assets</i>		<u>1,654,310</u>	<u>1,140,395</u>
<b>Non-current assets</b>			
Property, plant and equipment	9	81,616	110,054
Right-of-use assets	10	406,035	525,689
Intangible assets	11	-	16,291
<i>Total non-current assets</i>		<u>487,651</u>	<u>652,034</u>
<b>TOTAL ASSETS</b>		<u>2,141,961</u>	<u>1,792,429</u>
<b>LIABILITIES</b>			
<b>Current liabilities</b>			
Trade and other payables	12	589,320	486,802
Employee benefits	13	119,917	94,953
Lease liabilities	14	120,265	110,123
<i>Total current liabilities</i>		<u>829,502</u>	<u>691,878</u>
<b>Non-current liabilities</b>			
Employee benefits	13	26,875	15,343
Lease liabilities	14	319,789	439,761
<i>Total non-current liabilities</i>		<u>346,664</u>	<u>455,104</u>
<b>TOTAL LIABILITIES</b>		<u>1,176,166</u>	<u>1,146,982</u>
<b>NET ASSETS</b>		<u>965,795</u>	<u>645,447</u>
<b>FUNDS</b>			
Accumulated funds		<u>965,795</u>	<u>645,447</u>
<b>TOTAL FUNDS</b>		<u>965,795</u>	<u>645,447</u>

The accompanying notes form part of these financial statements

**ARCS AUSTRALIA LIMITED****STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME  
FOR THE YEAR ENDED 30 JUNE 2021**

	Note	2021 \$	2020 \$
<b>Revenue</b>	4	2,492,978	2,376,114
<b>Other income</b>	4	90,168	-
		<u>2,583,146</u>	<u>2,376,114</u>
<b>Expenses</b>			
Administration and other expenses		(247,611)	(268,949)
Course expenses		(789,915)	(860,151)
Depreciation and amortisation	5	(167,975)	(175,462)
Employee costs	5	(1,030,870)	(1,126,585)
Fair value loss on financial assets	5	-	(48,857)
Finance costs - leases	5	(22,162)	(27,211)
Project funding		-	(49,486)
Occupancy costs		(4,265)	(4,686)
		<u>(2,262,798)</u>	<u>(2,561,387)</u>
<b>Surplus (deficit) before income tax</b>		320,348	(185,273)
Income tax expense		-	-
<b>Surplus (deficit) for the year</b>		320,348	(185,273)
<b>Other comprehensive income</b>		-	-
<b>Total comprehensive income (loss) for the year</b>		<u><u>320,348</u></u>	<u><u>(185,273)</u></u>

The accompanying notes form part of these financial statements

**ARCS AUSTRALIA LIMITED****STATEMENT OF CHANGES IN FUNDS**  
**FOR THE YEAR ENDED 30 JUNE 2021**

	<b>Accumulated Funds</b>	<b>Total</b>
	<b>\$</b>	<b>\$</b>
<b>Balance at 1 July 2019</b>	830,720	830,720
<b>Comprehensive income</b>		
Surplus (deficit) for the year	(185,273)	(185,273)
Other comprehensive income	-	-
<b>Total comprehensive income (loss) for the year</b>	<u>(185,273)</u>	<u>(185,273)</u>
<b>Balance at 30 June 2020</b>	<u><b>645,447</b></u>	<u><b>645,447</b></u>
<b>Balance at 1 July 2020</b>	645,447	645,447
<b>Comprehensive income</b>		
Surplus (deficit) for the year	320,348	320,348
Other comprehensive income	-	-
<b>Total comprehensive income (loss) for the year</b>	<u>320,348</u>	<u>320,348</u>
<b>Balance at 30 June 2021</b>	<u><b>965,795</b></u>	<u><b>965,795</b></u>

**ARCS AUSTRALIA LIMITED****STATEMENT OF CASH FLOWS  
FOR THE YEAR ENDED 30 JUNE 2021**

	Note	2021 \$	2020 \$
<b>Cash flows from operating activities</b>			
Receipts from customers and government		2,484,423	2,342,167
Payments to suppliers and employees		(2,120,209)	(2,509,590)
Interest and investments received		7,366	29,108
Interest paid - leases		(22,162)	(27,211)
<i>Net cash flows from operating activities</i>		<u>349,418</u>	<u>(165,526)</u>
<b>Cash flows from investing activities</b>			
Proceeds from sale of financial assets		-	50,000
Purchase of property, plant and equipment		(3,592)	(4,496)
Purchase of financial assets		(4,611)	(18,188)
<i>Net cash flows from investing activities</i>		<u>(8,203)</u>	<u>27,316</u>
<b>Cash flows from financing activities</b>			
Repayments of lease liabilities		(109,830)	(99,496)
<i>Net cash flows from financing activities</i>		<u>(109,830)</u>	<u>(99,496)</u>
Net increase (decrease) in cash and cash equivalents		231,385	(237,706)
Cash and cash equivalents at the beginning of the financial year		<u>302,615</u>	<u>540,321</u>
Cash and cash equivalents at the end of the financial year	6	<u><u>534,000</u></u>	<u><u>302,615</u></u>

The accompanying notes form part of these financial statements

**ARCS AUSTRALIA LIMITED****NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2021****Note 1 - Reporting entity**

The financial report includes the financial statements and notes of ARCS Australia Limited. ARCS Australia Limited is registered as a company limited by guarantee and not having a share capital under the provisions of the *Australian Charities and Not-for-profits Commission Act 2012*.

The financial statements were approved by the Board of Directors on 30 September 2021.

**Note 2 - Basis of preparation*****Statement of compliance***

ARCS Australia Limited has adopted Australian Accounting Standards - Reduced Disclosure Requirements as set out in *AASB 1053 Application of Tiers of Australian Accounting Standards* and *AASB 2010-2: Amendments to Australian Accounting Standards arising from Reduced Disclosure Requirements*.

These financial statements are general purpose financial statements that have been prepared in accordance with Australian Accounting Standards - Reduced Disclosure Requirements and the *Australian Charities and Not-for-profits Commission Act 2012*. The company is a not-for-profit entity for financial reporting purposes under Australian Accounting Standards.

Australian Accounting Standards set out accounting policies that the AASB has concluded would result in financial statements containing relevant and reliable information about transactions, events and conditions.

***Basis of measurement***

The financial statements, except for the cash flow information, have been prepared on an accruals basis and are based on historical costs, modified, where applicable, by the measurement at fair value of selected non-current assets, financial assets and financial liabilities.

***Currency and rounding of amounts***

The financial statements are presented in Australian dollars, which is the company's functional and presentation currency.

***Comparatives***

Where required by Accounting Standards or to achieve consistency in financial statements presentation, the prior year financial comparatives have been adjusted to conform with current year disclosures and allow comparison with current financial year disclosures.

***Critical accounting estimates and judgements***

The Directors evaluate estimates and judgements incorporated into the financial statements based on historical knowledge and best available current information. Estimates assume a reasonable expectation of future events and are based on current trends and economic data, obtained both externally and within the company.

**Key estimates*****Impairment***

The Directors assess impairment at the end of each reporting period by evaluation of conditions and events specific to the company that may be indicative of impairment triggers. Recoverable amounts of relevant assets are reassessed using value-in-use calculations which incorporate various key assumptions.

***Long service leave provision***

The liability for long service leave is recognised and measured at the present value of the estimated future cash flows to be made in respect of all employees at the reporting date. In determining the present value of the liability, estimates of rates and pay increases through promotion and inflation have been taken into account.

**ARCS AUSTRALIA LIMITED**

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2021**

**Note 2 - Basis of preparation (continued)**

***New and revised standards that are effective for these financial statements***

Several amendments to Australian Accounting Standards and interpretations are mandatory for the 30 June 2021 reporting period. These include:

- *AASB 2018-6: Definition of a Business* (amendments to AASB 3)
- *AASB 2018-7: Definition of Material* (amendments to AASB 101 and AASB 108)
- *AASB 2019-1: References to the Conceptual Framework* (revises the Conceptual Framework for Financial Reporting)
- *AASB 2020-4: Amendments to AASs - Covid-19-Related Rent Concessions* (amendments to AASB 16)

The amendments listed above did not have any impact on the amounts recognised in the current or prior periods but may affect future periods.

***New standards and interpretations not yet adopted***

Certain new accounting standards, amendments and interpretations have been published that are not mandatory for 30 June 2021 reporting periods and have not been early adopted by the company. These include:

- *AASB 1060: General Purpose Financial Statements - Simplified Disclosures for For-Profit and Not-for-Profit Tier 2 Entities* (effective for the year ending 30 June 2022)
- *AASB 2020-1: Amendments to AASs - Classification of Liabilities as Current or Non-current* (effective for the year ending 30 June 2024)

It is not expected that AASB 2020-1 will have a material impact on the company in future reporting periods. AASB 1060 may have a material impact on the company in future reporting periods and on foreseeable future transactions and disclosures since AASB 1060 acts to mandate that the company prepare a general purpose financial report under a new Simplified Disclosure Standard in future reporting periods. The company has not yet assessed the specific financial reporting impacts of AASB 1060.

**Note 3 - Significant accounting policies**

The principal accounting policies adopted in the preparation of the financial report are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

***Income Tax***

ARCS Australia Limited is a not-for-profit Charity & public educational institution and it is exempt from income tax under Division 50 of the *Income Tax Assessment Act 1997*.

***Goods and Services Tax (GST)***

Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Australian Taxation Office (ATO). Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the ATO is included with other receivables or payables in the statement of financial position.

Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to, the ATO are presented as operating cash flows included in receipts from customers or payments to suppliers.

***Revenue recognition***

Revenue is measured at the fair value of the consideration received or receivable. All revenue is stated net of the amount of goods and services tax (GST). Revenue is recognised for the major business activities as follows:

***Interest***

Interest revenue is recognised as it accrues using the effective interest method.

**ARCS AUSTRALIA LIMITED****NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2021****Note 3 - Significant accounting policies (continued)*****Revenue recognition (continued)******Sales revenue***

Revenue from member subscriptions, seminars, training sessions, workshops and advertising is recognised when the amount of revenue can be measured reliably, and it is probable that it will be received by the Company. Revenue in advance is accounted for when invoices are raised, or funds are received in respect of events occurring in the subsequent financial year.

***Other revenue***

Other revenue is recognised when it is received or when the right to receive payment is established.

***Expenditure***

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category.

Management and administration costs are those incurred in connection with administration of the company and compliance with constitutional and statutory requirements.

***Cash and cash equivalents***

Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to insignificant risk of changes in value.

***Trade receivables***

Trade receivables are recognised initially at fair value and subsequently measured at amortised cost, less a provision for impairment. Collectability of trade receivables is reviewed on an ongoing basis. Debts which are known to be uncollectible are written off. A provision for impairment is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of receivables.

***Property, plant and equipment*****Recognition and measurement**

Each class of property, plant and equipment is carried at cost less, where applicable, any accumulated depreciation and impairment losses. Cost includes expenditure that is directly attributable to the acquisition of the items. Gains and losses on disposals are determined by comparing proceeds with carrying amount. These are included in the statement of profit or loss and other comprehensive income.

**Depreciation**

The depreciable amount of all property, plant and equipment including buildings, but excluding freehold land, is depreciated on a straight-line basis over the asset's useful life to the company commencing from the time the asset is held ready for use.

The depreciation effective life used for each class of depreciable assets is:

Office equipment & furniture	3 - 10 years
Software	4 years
Leasehold improvements	5 years

The assets' residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period. An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

**ARCS AUSTRALIA LIMITED****NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2021****Note 3 - Significant accounting policies (continued)*****Right-of-use assets***

At inception, a right-of-use assets and a lease liability is recognised. Right-of-use assets are included in the *Statement of Financial Position* within a classification relevant to the underlying asset.

Right-of-use assets are initially measured at cost, comprising of the following:

- the amount of the initial measurement of the lease liability
- Any lease payments made at or before the commencement date, less any lease incentives received
- Any initial direct costs incurred
- An estimate of costs to be incurred in dismantling and removing the underlying asset, restoring the site on which it is located or restoring the underlying asset to the condition required by the terms and conditions of the lease, unless those costs are incurred either at the commencement date or as a consequence of having used the underlying asset during a particular period

Subsequently, right-of-use assets are measured using a cost model. The right-of-use asset is depreciated to the earlier of the useful life of the asset or the lease term using the straight-line method and is recognised in the statement of profit or loss and other comprehensive income in "Depreciation and amortisation".

The company tests for impairment where there is an indication that a right-of-use asset may be impaired. An assessment of whether there is an indication of possible impairment is done at each reporting date. Where the carrying amount of a right of use asset is greater than the estimated recoverable amount, it is written down immediately to its recoverable amount. The resulting impairment loss is recognised immediately in surplus or deficit, except where the decrease reverses a previously recognised revaluation increase for the same asset.

The resulting decrease is recognised in other comprehensive income to that extent and reduces the amount accumulated in equity under revaluation surplus, and future depreciation charges are adjusted in future periods to allocate the revised carrying amount, less its residual value, on a systematic basis over its remaining useful life.

***Leases***

The company leases office premises on an arm's length basis from a third-party and related party lessor. A lease is a contract, or part of a contract, that conveys the right to use an asset for a period of time in exchange for consideration.

At inception of a contract, it is assessed to determine whether the contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. If the terms and conditions of a contract are changed, it is reassessed to once again determine if the contract is still, or now contains, a lease.

The term of a lease is determined as the non-cancellable period of the lease, together with the periods covered by an option to extend the lease where there is reasonable certainty that the option will be exercised, and periods covered by an option to terminate the lease if there is reasonable certainty that the option will not be exercised.

The assessment of the reasonable certainty of the exercising of options to extend the lease, or not exercising of options to terminate the lease, is reassessed upon the occurrence of either a significant event or a significant change in circumstances that is within the company's control, and it affects the reasonable certainty assumptions. The assessment of the lease term is revised if there is a change in the non-cancellable lease period.

The company does not recognise leases that have a lease term of 12 months or less or are of low value as a right-of-use asset or lease liability. The lease payments associated with these leases are recognised as an expense in the *Statement of Profit or Loss and Other Comprehensive Income* on a straight-line basis over the lease term.

**ARCS AUSTRALIA LIMITED**

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2021**

**Note 3 - Significant accounting policies (continued)**

***Lease liability***

At the commencement date of the lease, the lease liability is initially recognised for the present value of non-cancellable lease payments discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the company's incremental borrowing rate.

The tenor of a lease includes any renewal period where the lessee is reasonably certain that they will exercise the option to renew. The company has reviewed all its leases and included any extensions where the company assessed it is reasonably certain the lease agreement will be renewed.

The lease payment used in the calculation of the lease liabilities should include variable payments when they relate to an index or rate. Where leases contain variable lease payments based on an index or rate at a future point in time, the company has used the incremental uplift contained in the lease or the respective Reserve Bank forward-looking CPI target for CPI-related increases.

In the absence of any floor or cap clauses in the lease agreements, the company measures the rent for the year under market review at an amount equal to the rent of the year preceding the market review increased by a fixed rate.

The lease liability is initially measured at the present value of the lease payments that are not yet paid at the commencement date. Lease payments are discounted using the relevant company's incremental borrowing rate. The incremental borrowing rate used for this calculation is dictated by the tenor of the lease and the location of the asset. The incremental borrowing rate is the rate the company would be charged on borrowings, provided by our banking partners. The weighted average incremental borrowing rate is 4.5%. The following lease payments being fixed payments, less any lease incentives receivable, are included where they are not paid at the commencement date.

Subsequently, the lease liability is measured by:

- increasing the carrying amount to reflect interest on the lease liability
- reducing the carrying amount to reflect the lease payments made
- remeasuring the carrying amount to reflect any reassessment or lease modifications or to reflect revised in-substance fixed lease payments

The unwind of the financial charge on the lease liabilities is recognised in the *Statement of Profit or Loss and Other Comprehensive Income* in "Finance costs" based on the company's incremental borrowing rate.

***Financial instruments***

**Initial recognition and measurement**

Financial assets and financial liabilities are recognised when the company becomes a party to the contractual provisions to the instrument. For financial assets this is equivalent to the date that the company commits itself to either purchase or sell the asset. Financial instruments are initially measured at fair value plus transactions costs except where the instrument is classified "at fair value through profit or loss" in which case transaction costs are expensed to profit or loss immediately.

Trade receivables are initially measured at the transaction price if the trade receivables do not contain a significant financing component

**Classification and subsequent measurement**

***Financial assets***

Financial assets other than those designated and effective as hedging instruments are classified upon initial recognition into the following categories:

- amortised cost
- equity instruments at fair value through other comprehensive income (FVOCI)
- fair value through profit or loss (FVPL)

**ARCS AUSTRALIA LIMITED**

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2021**

**Note 3 - Significant accounting policies (continued)**

***Financial instruments (continued)***

All income and expenses relating to financial assets that are recognised in profit or loss are presented within finance income or finance costs, except for impairment of trade receivables which are disclosed with other expenses.

Measurement is on the basis of two primary criteria:

- the contractual cash flow characteristics of the financial asset
- the business model for managing the financial asset

*Financial assets at amortised cost*

Financial assets are measured at amortised cost if the asset meets the following conditions (and are not designated as FVPL):

- the financial asset is managed solely to collect contractual cash flows
- the contractual terms within the financial asset give rise to cash flows that are solely payments of principal and interest on the principal amount outstanding on specified dates

*Equity instruments at fair value through other comprehensive income*

Investments in equity instruments that are not held for trading are eligible for an irrevocable election at inception to be measured at fair value through other comprehensive income. Subsequent movements in fair value are recognised in other comprehensive income and are never reclassified to profit or loss. Dividend revenue received on underlying equity instruments investment will still be recognised in profit or loss unless the dividend clearly represents return of capital.

By default, all other financial assets that do not meet the measurement conditions of amortised cost and fair value through other comprehensive income are subsequently measured at fair value through profit or loss.

*Financial assets at fair value through profit or loss*

Financial assets that are held within a different business model other than to “hold and collect” or “hold to collect and sell” are categorised at fair value through profit or loss. The initial designation of financial instruments to measure at fair value through profit or loss is a one-time option on initial classification and is irrevocable until the financial asset is derecognised.

*Impairment of financial assets*

The impairment requirements as applicable under AASB 9 use more forward-looking information to recognise expected credit losses. Expected credit losses are the probability-weighted estimate of credit losses over the expected life of a financial instrument. A credit loss is the difference between all contractual cash flows that are due, and all cash flows expected to be received, all discounted at the original effective interest rate of the financial instrument

The Directors considers a broad range of information when assessing credit risk and measuring expected credit losses, including past events, current conditions, reasonable and supportable forecasts that affect the expected collectability of the future cash flows of the instrument. In applying this approach, a distinction is made between:

- financial instruments that have not deteriorated significantly in credit quality since initial recognition or that have low credit risk
- financial instruments that have deteriorated significantly in credit quality since initial recognition and the credit risk is not low
- financial assets that have objective evidence of impairment at reporting date

The loss allowance for the first category is measured as “12-month expected credit loss” and for the second category is measured as “lifetime expected credit losses”.

**ARCS AUSTRALIA LIMITED****NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2021****Note 3 - Significant accounting policies (continued)*****Trade and other payables***

Trade and other payables represent the liability outstanding at the end of the reporting period for goods and services received by the Company during the reporting period, which remain unpaid. The balance is recognised as a current liability with the amounts normally paid within 30 days of recognition of the liability. The carrying amount of trade and other payables is deemed to reflect fair value.

***Employee benefits***

Provision is made for the company's liability for employee benefits arising from services rendered by employees to the end of the reporting period. Employee benefits that are expected to be settled within one year have been measured at the amounts expected to be paid when the liability is settled. Employee benefits payable later than one year have been measured at the present value of the estimated future cash outflows to be made for those benefits. In determining the liability, consideration is given to employee wage increases and the probability that the employee may not satisfy vesting requirements. Those cash outflows are discounted using market yields on high quality corporate bonds with terms to maturity that match the expected timing of cash flows.

***Fair value of intangible assets***

The estimated useful life of the database and related website is 4 years from the date on which the asset was first completed and ready for use. Should that useful life vary (up or down), then the resulting provision for amortisation might have a material impact on that intangible asset.

**ARCS AUSTRALIA LIMITED****NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2021**

	2021 \$	2020 \$
<b><u>Note 4 - Revenue</u></b>		
<b>Revenue</b>		
Membership subscriptions	330,512	347,567
Education activities	1,742,776	1,732,571
Grants revenue	66,724	49,486
Partnership income*	115,500	84,828
	<u>2,255,512</u>	<u>2,214,452</u>
<b>Other revenue</b>		
Interest income	1,365	5,505
Investments revenue	6,001	23,603
Government support - COVID-19	225,792	113,000
Other revenue	4,308	19,554
	<u>237,466</u>	<u>161,662</u>
<i>Total revenue</i>	<u>2,492,978</u>	<u>2,376,114</u>
<b>Other income</b>		
Fair value gain on financial assets	90,168	-
<i>Total other income</i>	<u>90,168</u>	<u>-</u>
<i>Total revenue and other income</i>	<u>2,583,146</u>	<u>2,376,114</u>
* A nominal amount of membership subscriptions have been included in partnership income.		
<b><u>Note 5 - Expenses</u></b>		
Depreciation and amortisation		
Property, plant and equipment	32,030	30,366
Right-of-use assets	119,654	123,691
Amortisation	16,291	21,405
<i>Total depreciation and amortisation</i>	<u>167,975</u>	<u>175,462</u>
Employee benefits expense	1,030,870	1,126,585
Finance costs - leases	22,162	27,211
Fair value loss on financial assets	-	48,857
<b><u>Note 6 - Cash and cash equivalents</u></b>		
Cash at bank	534,000	302,615
<i>Total cash and cash equivalents</i>	<u>534,000</u>	<u>302,615</u>
<b><u>Note 7 - Trade and other receivables</u></b>		
<b><u>Current</u></b>		
Trade receivables	376,067	119,370
Other receivables	54,009	10,343
Prepayments	21,203	133,815
<i>Total current trade and other receivables</i>	<u>451,279</u>	<u>263,528</u>

## ARCS AUSTRALIA LIMITED

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2021**

	2021	2020
	\$	\$
<b>Note 8 - Financial assets</b>		
<u>Current</u>		
Financial assets at fair through profit or loss		
Held to maturity investments	100,634	100,634
Managed funds	568,397	473,618
<i>Total financial assets</i>	<u>669,031</u>	<u>574,252</u>
<b>(a) Movement in held to maturity investments</b>		
Opening net carrying amount	100,634	150,634
Disposals	-	(50,000)
Closing net carrying amount	<u>100,634</u>	<u>100,634</u>
<b>(b) Movement in managed funds</b>		
Opening net carrying amount	473,618	504,287
Additions	4,611	18,188
Fair value gain (loss)	90,168	(48,857)
Closing net carrying amount	<u>568,397</u>	<u>473,618</u>

**Note 9 - Property, plant and equipment**

	Leasehold Improvements	Equipment	Total
	\$	\$	\$
<b>At 30 June 2020</b>			
Cost	154,837	33,443	188,280
Accumulated depreciation	(62,943)	(15,283)	(78,226)
<i>Net carrying amount</i>	<u>91,894</u>	<u>18,160</u>	<u>110,054</u>
<b>Movements in carrying amounts</b>			
Opening net carrying amount	91,894	18,160	110,054
Additions	-	3,592	3,592
Depreciation charge for the year	(20,806)	(11,224)	(32,030)
Closing net carrying amount	<u>71,088</u>	<u>10,528</u>	<u>81,616</u>
<b>At 30 June 2021</b>			
Cost	154,837	37,036	191,873
Accumulated depreciation	(83,749)	(26,508)	(110,257)
<i>Net carrying amount</i>	<u>71,088</u>	<u>10,528</u>	<u>81,616</u>

	2021	2020
	\$	\$
<b>Note 10 - Right-of-use assets</b>		
Leased office - at cost	649,380	649,380
Accumulated depreciation	(243,345)	(123,691)
<i>Total right-of-use assets</i>	<u>406,035</u>	<u>525,689</u>
<b>Movements in carrying amounts</b>		
Opening net carrying amount	525,689	649,380
Depreciation charge for the year	(119,654)	(123,691)
Closing net carrying amount	<u>406,035</u>	<u>525,689</u>

## ARCS AUSTRALIA LIMITED

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2021**

**Note 11 - Intangible assets**

	Software \$	Website Development \$	Total \$
<b>At 30 June 2020</b>			
Cost	3,340	82,358	85,698
Accumulated amortisation	(3,340)	(66,067)	(69,407)
<i>Net carrying amount</i>	<u>-</u>	<u>16,291</u>	<u>16,291</u>
<b>Movements in carrying amounts</b>			
Opening net carrying amount	-	16,291	16,291
Amortisation charge for the year	-	(16,291)	(16,291)
Closing net carrying amount	<u>-</u>	<u>-</u>	<u>-</u>
<b>At 30 June 2021</b>			
Cost	3,340	82,358	85,698
Accumulated amortisation	(3,340)	(82,358)	(85,698)
<i>Net carrying amount</i>	<u>-</u>	<u>-</u>	<u>-</u>
	<b>2021</b>	<b>2020</b>	
	<b>\$</b>	<b>\$</b>	

**Note 12 - Trade and other payables**Current

Trade payables	23,252	58,983
Income in advance	395,231	324,934
Liabilities to employees	44,949	42,527
Other payables	125,888	60,358
<i>Total current trade and other payables</i>	<u>589,320</u>	<u>486,802</u>

**Note 13 - Employee Benefits**Current

Annual leave	86,339	61,019
Long service leave	33,578	33,934
<i>Total current employee benefits</i>	<u>119,917</u>	<u>94,953</u>

Non-current

Long service leave	26,875	15,343
<i>Total non-current employee benefits</i>	<u>26,875</u>	<u>15,343</u>

**Note 14 - Lease liabilities**Current

Lease liabilities	120,265	110,123
<i>Total current lease liabilities</i>	<u>120,265</u>	<u>110,123</u>

Non-current

Lease liabilities	319,789	439,761
<i>Total non-current lease liabilities</i>	<u>319,789</u>	<u>439,761</u>

**Movements in carrying amounts**

Opening net carrying amount	549,884	649,380
Repayments	(131,992)	(126,707)
Interest	22,162	27,211
Closing net carrying amount	<u>440,054</u>	<u>549,884</u>

**ARCS AUSTRALIA LIMITED****NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2021**

	2021	2020
	\$	\$

**Note 15 - Key management personnel compensation**

The aggregate amount of compensation paid to key personnel during the year was:	<u>371,405</u>	<u>511,125</u>
---	----------------	----------------

**Note 16 - Contingent liabilities**

At balance date the Directors of the company are not aware of the existence of any contingent liability.

**Note 17 - Related party transactions*****Director's Compensation***

No Director received remuneration in the current and previous financial years.

**Note 18 - Events occurring after balance date**

Subsequent to the end of the financial year, there remains a degree of uncertainty in relation to future economic and other impacts of the COVID-19 pandemic, emergency control measures and progressive withdrawal of Government emergency support.

At the date of signing the financial statements the Directors are unable to determine what financial effects the outbreak of the virus could have on the company in the coming financial period.

The Directors acknowledge their responsibility to continuously monitor the situation and evaluate this impact including its ability to pay its debts as and when they become due and payable.

There were no significant events occurring after the balance sheet date.

**ARCS AUSTRALIA LIMITED**

**ABN 25 050 334 444**


**FINANCIAL REPORT - 30 JUNE 2021**

**DIRECTORS' DECLARATION**

The Directors of the ARCS Australia Limited declare that:

1. The financial statements, which comprises the statement of financial position as at 30 June 2021, and the statement of profit or loss and other comprehensive income, statement of changes in funds and statement of cash flows for the year ended on that date, a summary of significant accounting policies and other explanatory notes are in accordance with the *Australian Charities and Not-for-profits Commission Act 2012* and:
  - (a) comply with Australian Accounting Standards - Reduced Disclosure Requirements (including Australian Accounting Interpretations) and the *Australian Charities and Not-for-profits Commission Regulation 2013*; and
  - (b) give a true and fair view of the financial position as at 30 June 2021 and of the performance for the year ended on that date of the company.
2. In the opinion of the Directors there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Board of Directors.

DocuSigned by:  
  
AE5A902088154E0...

Arthur Brandwood

Director

Sydney, 30 September 2021

**ARCS AUSTRALIA LIMITED**  
**ABN 25 050 334 444**

**FINANCIAL REPORT - 30 JUNE 2021**

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF**  
**ARCS AUSTRALIA LIMITED**

***Opinion***

We have audited the financial report of ARCS Australia Limited which comprises the statement of financial position as at 30 June 2021, the statement of profit or loss and other comprehensive income, the statement of changes in funds and statement of cash flows for the year then ended, notes comprising a summary of significant accounting policies and other explanatory information, and the Directors' Declaration.

In our opinion, the accompanying financial report of ARCS Australia Limited is in accordance with the *Australian Charities and Not-for-profits Commission Act 2012*, including:

- a) giving a true and fair view of the company's financial position as at 30 June 2021 and of its financial performance for the year then ended, and
- b) complying with Australian Accounting Standards - Reduced Disclosure Requirements (including Australian Accounting Interpretations) and the *Australian Charities and Not-for-profits Commission Regulation 2013*.

***Basis for Opinion***

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibility for the Audit of the Financial Report* section of our report. We are independent of the company in accordance with the auditor independence requirements of the *Australian Charities and Not-for-profits Commission Act 2012* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Australian Charities and Not-for-profits Commission Act 2012*, which has been given to the Directors of the company, would be in the same terms if given to the Directors as at the time of this auditor's report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

***Directors' Responsibility for the Financial Report***

The Directors of the company are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards - Reduced Disclosure Requirements and the *Australian Charities and Not-for-profits Commission Act 2012* and for such internal control as the Directors determine is necessary to enable the preparation of a financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the Directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

The Directors are responsible for overseeing the company's financial reporting process.

**ARCS AUSTRALIA LIMITED****ABN 25 050 334 444****FINANCIAL REPORT - 30 JUNE 2021****INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF**  
**ARCS AUSTRALIA LIMITED*****Auditor's Responsibilities for the Audit of the Financial Report***

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

A further description of our responsibilities for the audit of the financial report is located at *The Auditing and Assurance Standards Board* and the website address is <http://www.auasb.gov.au/Home.aspx>

We communicate with the Directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



**StewartBrown**  
Chartered Accountants



**S.J. Hutcheon**  
Partner

30 September 2021



**[www.arcs.com.au](http://www.arcs.com.au)**

**E: [arcs@arcs.com.au](mailto:arcs@arcs.com.au)**

**T: 02 8905 0829**

